FBM-PHARMA – the specialist for individual immunotherapeutic medicines

FBM-PHARMA „Gesellschaft für biologische Medizin mbH“, founded in 1995, focusses on manufacture of individual immunotherapeutic medicines based on patient’s material (blood/urine). 

The complementary medical treatment approach is used in the causal therapy of autoimmune diseases of various types: 

  • Chronic inflammation of the skin, such as psoriasis, neurodermatitis or eczema
  • Chronic inflammatory respiratory diseases, such as COPD, pulmonary fibrosis or bronchial asthma
  • Chronic inflammation of the gastrointestinal tract, such as Crohn’s disease or ulcerative colitis 

The individual immunotherapeutic medicines (individual immunotherapy from blood/plasma, AHIT® according to Dr. Kief, urexent®) meanwhile was administered to more than 17,000 patients and showed in many of them sustainable improvement in health status. Detailed information can be found on the company website (www.fbm-pharma.de). 

The extraordinary therapeutic approach is based on processing of the body's own, disease-related substances to a personalized drug and is thus a unique, causal form of therapy in the treatment of the above-mentioned diseases. 

The immunomodulatory therapy is almost free of side effects and can be used from infancy onwards.

FBM-PHARMA owns a manufacturing authorization for the production of biological medicines based on the patient's own blood and urine and is subject to regular inspection by the competent authority. 

Core competences of FBM-PHARMA are the continuous development of the existing preparations as well as the establishment of new products. 

Currently, FBM-PHARMA is seeking to expand the manufacturing license for autologous serum eye drops, with the aim of closing the existing gap in comprehensive outpatient care.